Skip to main navigation
Skip to search
Skip to main content
the UWA Profiles and Research Repository Home
Login
Home
Profiles
Organisations
Research output
Grants
Datasets
Prizes / Awards
Engagement / Activities
Press/Media
Units
Equipment
Impacts
Search by expertise, name or affiliation
Immunological biomarkers of outcome in thoracic cancers
Tarek Mohamed Meniawy
Research output
:
Thesis
›
Doctoral Thesis
581
Downloads (Pure)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Immunological biomarkers of outcome in thoracic cancers'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Biological Marker
100%
Thoracic Cancer
100%
Patient
100%
Ligand
63%
Therapeutic Procedure
63%
Non Small Cell Lung Cancer
45%
Epidermal Growth Factor Receptor Kinase Inhibitor
45%
T Cell
45%
Receptor
36%
Immunotherapy
27%
Immune System
27%
Development
27%
Neoplasm
18%
Overall Survival
18%
Solid Malignant Neoplasm
18%
Dendritic Cell
18%
Epidermal Growth Factor Receptor
18%
Targeted Therapy
18%
Exercise
9%
Radiation Therapy
9%
Serositis
9%
Histology
9%
Univariate Analysis
9%
Peripheral Blood Mononuclear Cell
9%
Tumor Cell
9%
Lymphocyte
9%
Flow Cytometry
9%
Age
9%
Platelet
9%
Multivariate Analysis
9%
Immunocompetent Cell
9%
Progressive Disease
9%
Rigor
9%
Treatment of Non-Small Cell Lung Cancer
9%
Tenidap
9%
Cells
9%
Comprehension
9%
Laboratory
9%
Enalapril Maleate
9%
Survival
9%
Inpatient
9%
Marker
9%
Weight Loss
9%
Donor
9%
Blood
9%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
100%
Malignant Neoplasm
100%
Ligand
63%
Non Small Cell Lung Cancer
54%
Epidermal Growth Factor Receptor Kinase Inhibitor
45%
Chemotherapy
36%
Receptor
36%
Neoplasm
27%
Immunotherapy
27%
Overall Survival
18%
Epidermal Growth Factor Receptor
18%
Solid Malignant Neoplasm
18%
Immune Checkpoint Inhibitor
18%
Diseases
9%
Inflammation
9%
Rigor
9%
Flow Cytometry
9%
Tenidap
9%
Survival
9%
Enalapril Maleate
9%
Thorax Pain
9%
Biochemistry, Genetics and Molecular Biology
Epidermal Growth Factor Receptor
63%
Mutation
45%
Receptor Tyrosine Kinase Inhibitors
45%
Development
27%
Dendritic Cell
18%
Overall Survival
18%
Solid
18%
CD4
9%
CD8
9%
Peripheral Blood Mononuclear Cell
9%
Flow Cytometry
9%
Age
9%
Platelet Count
9%
Exercise
9%
Contrast
9%
Immunocompetent Cell
9%
Dynamics
9%
Time
9%
Comprehension
9%
Sequencing
9%
Survival
9%
Multivariate Analysis
9%
Weight
9%
Neuroscience
Ligand
63%
Eicosanoid Receptor
36%
Immunotherapy
27%
Chemotherapy
18%
Platelet
9%
Histology
9%
CD4
9%
CD8
9%
Flow Cytometry
9%
Peripheral Blood Mononuclear Cell
9%